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Editors’ NotesStemming Neural Disorder
Many neural disorders result from the loss of specific neuronal subtypes. Parkinson’s disease, for instance, is caused by the degen-
eration of dopaminergic neurons in the substantia nigra. In this issue, Jaenisch and colleagues convert mouse fibroblasts into
induced dopaminergic neurons (iDA) and transplant these cells into the brains of mice that have undergone lesions to mimic the
neural loss that occurs in the disease. The authors show that the iDAs successfully graft into the lesioned brains, appear morpho-logically normal, and express dopamine, although it is yet to be determined
whether parkinsonian symptoms are suppressed after such a transplant.
The work provides evidence of the potential utility of stem cell therapies in
translational medicine; however, themove frombench to bedside is impacted
by more than basic research. For insight into the complex issues facing the
cell therapy industry, see the Forum from Brindley and colleagues detailing
the health and outlook of the industry based on stock market analysis, and
see the Letter from Lysaght and colleagues discussing the legal quagmire
in the US over the regulation of stem-cell-based treatments. In addition to
serving as potential treatments for brain disorders, new research also points
to stem cells as the source of neural dysfunction in some instances. Galli and
colleagues developed a new mouse model for Tuberous Sclerosis Complex
(TSC), a genetic disorder with associated neurological lesions, and found
that disrupting mTOR regulation of the neural stem cell compartment recapit-
ulated key neurological features of the disease. This newmouse model could
be a useful tool in preclinical trials for therapeutics aimed at TSC.A Regenerational Divide
Stem cells play a key role in long-term tissue homeostasis and response to injury
(see the Review by Jasper on somatic stem cell regulation in maintaining barrier
epithelia). In the germline, spermatogenesis depends upon the continuous divi-
sion of spermatogonial stem cells (SSCs). Transplantation of SSCs is a potential
therapy for infertility, but the limiting step has been homing to the SSC niche,
which requires that cells pass through the blood-testis barrier. In this issue, Shi-
nohara and colleagues show that the small G protein Rac regulates transmigra-
tion through the barrier and SSC proliferation, identifying Rac as a potential
target for increasing the efficiency of stem-cell-based infertility treatment. In
contrast to this system of robust self-renewal, many somatic tissues—such as
the heart—are less prone to regeneration, making repair after injury difficult. In
adult mammals, cardiomyocytes cannot regenerate but do dedifferentiate after
injury, and recent studies have suggested the existence of a pool of cardiac stem
cells, tantalizing evidence that some form of regeneration may be possible. New
research from Braun and colleagues (see also the Preview fromMorrisey) shows
that this postinjury dedifferentiation is induced by an inflammatory cytokine, on-
costatin M, which also increases expression of stem cell markers. Interestingly,
the effects of oncostatinM appear specific to the type of cardiac injury. The cyto-
kine benefits recovery after acute insults such as myocardial infarction, presum-
ably by allowing short-term dedifferentiation and remodeling, yet hinders
recovery from chronic insults, such as dilated cardiomyopathy. The authors
propose that this dichotomy could be related to the high cardiac output needed
in adult mammals; long-term dedifferentiation may reduce contractile force and
favor ventricular dilation, thereby contributing to heart failure.Eyeing the Target
For many aggressive cancers, cancer stem cells (CSCs) are believed to be a major culprit behind the high tumor recurrence, metas-
tasis, and resistance to chemo and radiation. As such, much effort has gone toward identifying CSCs within the larger tumor pop-
ulation, and finding ways to specifically target them therapeutically. Heeschen and colleagues provide exciting evidence that in
pancreatic cancer, which has a particularly devastating prognosis, the Nodal/Activin signaling pathway is essential for the self-
renewal properties of pancreatic CSCs (see also the Preview by Donahue and Dawson). Using a combination of drugs that included
an inhibitor of Nodal/Activin signaling, the chemotherapeutic gemcitabine, and a stroma inhibitor, the authors halted tumor progres-
sion in xenografts of human pancreatic tumors, suggesting that such a cocktail could be a useful treatment model for some patients.
Also in this issue, Medema and colleagues reexamine the CSC gene signature in colorectal cancer, and find that while the colon-CSC
signature is enriched for Wnt target genes (Wnt signaling is known to be high in these cells), expression of these genes is actually
suppressed by promoter methylation and this correlates with poor prognosis. The results suggest that therapeutics targeted at
increasing expression of these genes could suppress metastasis and prevent disease progression.Cell Stem Cell 9, November 4, 2011 ª2011 Elsevier Inc. xi
